The company's financial position is increasingly fragile, characterized by a $202.9 million debt burden and a negative equity position of $161.5 million as of 2026Q1.
| Total Current Assets | 124.54M | 167.64M | 309.89M | 306.52M | 261.88M | 331.78M | 522.32M | 409.32M | 231.95M | 445K | 60K |
| Cash & Short-Term Investments | 99.22M | 136.93M | 294.52M | 296.43M | 255.68M | 325.22M | 512.63M | 401.77M | 228.66M | 315K | 60K |
| Cash Only | 41.03M | 37.73M | 46.07M | 32.11M | 111.97M | 183.4M | 486.06M | 135.03M | 105.22M | 315K | 60K |
| Short-Term Investments | 58.19M | 99.2M | 248.44M | 264.32M | 143.71M | 141.81M | 26.57M | 266.74M | 123.44M | 0 | 0 |
| Accounts Receivable | 9.35M | 12.53M | 5.34M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | 64.9 | 94.33 | 16.99 | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 15.97M | 18.18M | 10.03M | 10.09M | 0 | 64K | 565K | 63K | 700K | 0 | 0 |
| Total Non-Current Assets | 4.36M | 4.61M | 5.4M | 5.4M | 10.57M | 11.88M | 17.11M | 17.29M | 7.47M | 0 | 0 |
| Property, Plant & Equipment | 3.96M | 4.2M | 5.12M | 4.78M | 9.89M | 10.8M | 16.08M | 15.73M | 3.19M | 0 | 0 |
| Fixed Asset Turnover | 12.89x | 11.55x | 22.40x | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 398K | 408K | 283K | 618K | 680K | 1.08M | 1.03M | 1.56M | 4.27M | 0 | 0 |
| Total Assets | 128.9M | 172.25M | 315.29M | 311.92M | 272.45M | 343.66M | 539.43M | 426.6M | 239.42M | 445K | 60K |
| Asset Turnover | 0.30x | 0.28x | 0.36x | - | - | - | - | - | - | - | - |
| Asset Growth % | -175.4% | -45.37% | 1.08% | 14.49% | -20.72% | -36.29% | 26.45% | 78.18% | 53702.02% | 641.67% | - |
| Total Current Liabilities | 56.51M | 63.44M | 45.01M | 51.6M | 49.23M | 39.86M | 38.65M | 36.92M | 20.4M | 1.27M | 143K |
| Accounts Payable | 10.82M | 5.96M | 2.32M | 5.53M | 1.46M | 3.24M | 7.51M | 956K | 2.18M | 97K | 40K |
| Days Payables Outstanding | 7.78K | 2.17K | - | - | - | - | 642.09 | 112.96 | 2.68K | - | - |
| Short-Term Debt | 957K | 938K | 0 | 11.61M | 11.61M | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 56.19M | 0 | 17.05M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 23.33M | 56.53M | 0 | 10.29M | 13.53M | 11.92M | 12.19M | 9.28M | 0 | 0 | 0 |
| Current Ratio | 2.20x | 2.64x | 6.88x | 5.94x | 5.32x | 8.32x | 13.51x | 11.09x | 11.37x | 0.35x | 0.42x |
| Quick Ratio | 2.20x | 2.64x | 6.88x | 5.94x | 5.32x | 8.32x | 13.51x | 11.09x | 11.37x | 0.35x | 0.42x |
| Cash Conversion Cycle | -7.71K | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 233.88M | 231.57M | 240.79M | 197.55M | 211.14M | 182.34M | 180.1M | 37.2M | 339.08M | 6.04M | 40K |
| Long-Term Debt | 198.76M | 198.51M | 197.52M | 197.41M | 207.7M | 179.12M | 172.39M | 28.46M | 0 | 6.04M | 40K |
| Capital Lease Obligations | 10.85M | 3.46M | 4.4M | 144K | 3.45M | 3.22M | 7.71M | 8.74M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 339.08M | 1K | 0 |
| Total Liabilities | 290.38M | 295.01M | 285.8M | 249.15M | 260.37M | 222.19M | 218.75M | 74.12M | 359.49M | 7.31M | 183K |
| Total Debt | 202.93M | 201.97M | 202.88M | 212.46M | 225.74M | 185.24M | 183.73M | 39.55M | 0 | 6.04M | 40K |
| Net Debt | 161.91M | 164.24M | 156.81M | 180.35M | 113.77M | 1.83M | -302.32M | -95.48M | -105.22M | 5.72M | -20K |
| Debt / Equity | -1.26x | - | 6.88x | 3.38x | 18.69x | 1.53x | 0.57x | 0.11x | - | - | - |
| Debt / EBITDA | -1.14x | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -0.91x | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -15.50x | -14.86x | -3.83x | -12.31x | -15.53x | -11.04x | -18.21x | - | -12246.42x | -56.38x | - |
| Total Equity | -161.48M | -122.76M | 29.49M | 62.77M | 12.08M | 121.46M | 320.68M | 352.49M | -120.07M | -6.86M | -123K |
| Equity Growth % | -3408.61% | -516.25% | -53.02% | 419.74% | -90.06% | -62.12% | -9.02% | 393.57% | -1649.77% | -5478.86% | - |
| Book Value per Share | -0.69 | -0.54 | 0.13 | 0.28 | 0.14 | 1.62 | 4.68 | 6.44 | -1.99 | -0.28 | -0.01 |
| Total Shareholders' Equity | -161.48M | -122.76M | 29.49M | 62.77M | 12.08M | 121.46M | 320.68M | 352.49M | -120.07M | -6.86M | -123K |
| Common Stock | 24K | 24K | 23K | 23K | 10K | 8K | 8K | 7K | 2K | 0 | 0 |
| Retained Earnings | -1.49B | -1.44B | -1.27B | -1.21B | -1.03B | -811.53M | -577.53M | -334.17M | -153.86M | -6.89M | -123K |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -4.02M | -5.15M | 1.19M | -350K | -574K | 45K | 599K | 258K | -61K | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Liquidity and capital dilution
As reported in recent financial statements, Gossamer Bio's equity position has deteriorated into a deficit of $161.5 million by 2026Q1, reflecting a persistent trend of capital consumption that outpaces the company's ability to generate value through its clinical development pipeline and strategic partnership milestones.
The shift from a positive equity base in 2024 to a significant deficit suggests that accumulated losses are rapidly eroding the company's net worth. Investors should monitor whether this trajectory necessitates further dilutive equity raises to restore a semblance of balance sheet stability.
Based on reported figures, the company carries a substantial debt load of $202.9 million as of 2026Q1, which, when coupled with a negative equity position, creates a highly leveraged profile that limits the firm's strategic options during its critical Phase 3 clinical trial phase.
The presence of significant debt on a balance sheet devoid of recurring product revenue suggests that interest obligations may further exacerbate the existing cash burn. This leverage appears to be a necessity-driven financing arrangement rather than a strategic choice, increasing the risk profile for equity holders.
According to recent SEC filings, the company's cash and equivalents of $41.0 million as of 2026Q1 provide a limited buffer against quarterly operating losses, suggesting that the firm's liquidity position is highly sensitive to the timing of milestone payments and clinical trial expenditure cycles.
While the current ratio of 2.20 appears superficially adequate, the underlying cash burn rate indicates that the company may face a liquidity crunch in the near term. The reliance on external capital to maintain operations underscores the vulnerability of the current balance sheet to market volatility.
Data from quarterly filings indicates that deferred revenue of $40.6 million as of 2026Q1 represents a significant portion of the company's liabilities, which may mislead investors regarding the firm's true financial health by inflating the appearance of future performance obligations versus actual cash-generating potential.
This deferred revenue is contingent upon clinical milestones rather than guaranteed commercial demand, meaning it does not provide the same stability as traditional recurring revenue. Analysts should interpret this figure as a liability that requires successful clinical execution to be extinguished, rather than a reliable source of future liquidity.
Quick answers to the most common questions about buying GOSS stock.
As of 2025, Gossamer Bio, Inc. (GOSS) had total assets of $172.2M including $167.6M in current assets.
Gossamer Bio, Inc. (GOSS) carries total debt of $202.0M, offset by $136.9M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Gossamer Bio, Inc. (GOSS) has total shareholders' equity (book value) of $-122.8M ($-0.54 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Gossamer Bio, Inc. (GOSS) reported a current ratio of 2.64x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.